Common questions regarding clinical use of axitinib in advanced renal cell carcinoma

American Journal of Health-System Pharmacy

Volumn 71, Issue 13, 2014, Pages 1092-1096

  Borst, Diane L ^a   Arruda, Lillian S ^a   MacLean, Elizabeth ^a   Pithavala, Yazdi K ^a   Morgado, James E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SOLUTION AND SOLUBILITY;

ARTICLE; BRAIN METASTASIS; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; COMORBIDITY; DRUG FORMULATION; DRUG PENETRATION; HUMAN; KIDNEY CARCINOMA; NASOGASTRIC TUBE; ADMINISTRATION AND DOSAGE; ANIMAL; CARCINOMA, RENAL CELL; DOSE RESPONSE; KIDNEY NEOPLASMS; MEDICINAL CHEMISTRY; SOLUTION AND SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; PHARMACEUTICAL SOLUTIONS; PROTEIN KINASE INHIBITORS;

EID: 84908482198     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130581     Document Type: Article

References (22)

1. Inlyta (axitinib) prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=759 (accessed 2014 Mar 30).
2. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378:1931-9.
3. Chen Y, Tortorici MA, Garrett M et al. Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013; 52:713-25.
4. Yang LP, McKeage K. Axitinib: in advanced, treatment-experienced renal cell carcinoma. Drugs. 2012; 72:2375-84.
5. Larkin J, Fishman M, Wood L et al. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol. Epub ahead of print. 2013 Jan 24 (DOI 10.1097/COC.0b013e31827b45f9).
6. Wood LS, Gornell S, Rini BI. Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management. Community Oncol. 2012; 9:46-55.
7. Charpentier MM, Orr KK, Taveira TH. Improving pharmacist knowledge of oral chemotherapy in the community. Ann Pharmacother. 2012; 46:1205-11.
8. Data on file, Pfizer, New York.
9. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:1172-93.
10. Neuss MN, Polovich M, McNiff K et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Oncol Nurs Forum. 2013; 40:225-33.
11. Tortorici MA, Toh M, Rahavendran SV et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs. 2011; 29:1370-80.
12. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007; 8:975-84.
13. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27:4462-8.
14. Rini BI, Melichar B, Ueda T et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013; 14:1233-42.
15. Hutson TE, Lesovoy V, Al-Shukri S et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013; 14:1287-94.
16. Poller B, Iusuf D, Sparidans RW et al. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos. 2011; 39:729-35.
17. Mignogna C, Staibano S, Altieri V et al. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer. 2006; 6:293.
18. Walsh N, Larkin A, Kennedy S et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009; 9:6.
19. Pithavala YK, Tong W, Mount J et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs. 2012; 30:273-81.
20. Pithavala YK, Tortorici M, Toh M et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol. 2010; 65:563-70.
21. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005; 23:5474-83.
22. Chen C, Assang M, Cisar L. Axitinib real-world dose titration experience from U.S. specialty pharmacy data. J Manag Care Pharm. 2013; 19:659.